Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Year: 2025
Type: letter
Source: New England Journal of Medicine
DOI: 10.1056/nejmc2515117
Authors: Julio Rosenstock, David Cox, Max Denning
Institutions: Medical City Dallas Hospital, Eli Lilly (United States)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417035355
